CStone Pharmaceuticals Doses First Patient in CS2009 Phase I Study for Solid Tumors
China-based CStone Pharmaceuticals (HKG: 2616) announced the first patient dosing in a global, multi-center Phase...
Cancer
Innovent Biologics Doses First Patient in IBI363 Melanoma Study vs Keytruda
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the pivotal regulatory...
Sinocelltech’s Finotonlimab Gets NMPA Approval for Liver Cancer Treatment
China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received another indication approval from...
Magnet Biomedicine and Eli Lilly Partner on Molecular Glue Therapeutics
US-based molecular glue specialist Magnet Biomedicine has entered into a collaboration and license agreement with...
CSPC Pharmaceutical’s Sirolimus Receives BTD for Malignant PEComa Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received Breakthrough Therapy Designation...
Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the sale of 4,947,181 shares in...
SciClone Pharmaceuticals Licenses Eisai’s Tasurgratinib for China
China-based SciClone Pharmaceuticals Inc. announced a licensing agreement with Eisai Co., Ltd (TYO: 4523), securing...
Akeso Inc. Completes Patient Enrollment for AK138D1 Phase I Study
China-based biotech Akeso Inc. (HKG: 9926) announced the completion of patient enrollment in the Phase...
Adagene Starts Phase II Trial of Muzastotug for Colorectal Cancer
China-based Adagene Inc. (NASDAQ: ADAG) announced the initiation of an Investigator-Initiated (IIT) Phase II trial...
Huadong Medicine’s ADC HDM2005 Granted FDA Orphan Drug Designation for MCL
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its antibody-drug conjugate (ADC) HDM2005 has...
Burning Rock and MGI Tech Partner to Advance Oncology Precision Medicine
China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has entered into a strategic partnership with...
Sanofi’s Sarclisa Wins New Japan Approval for Multiple Myeloma Combination Therapy
Sanofi (EPA: SAN, NASDAQ: SNY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW)...
Merck’s Keytruda sBLA for LA-HNSCC Accepted by FDA for Review
Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that the US Food and Drug...
Summit Therapeutics and Pfizer Collaborate on Ivonescimab-ADC Combo for Solid Tumors
Summit Therapeutics Inc. (NASDAQ: SMMT), the U.S. partner of China-based Akeso Inc. (HKG: 9926) for...
Bristol-Myers Squibb’s Opdivo-Yervoy Combo Nears FDA Approval for MSI-H Colorectal Cancer
Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the U.S. FDA has accepted its filing for...
MGI Tech Partners with Oncoclínicas&Co to Advance Precision Medicine in Brazil
China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) has partnered with OC Medicina...
AWS Collaborates with MSK to Accelerate Oncology Research via AI and Cloud Tech
Amazon Web Services (AWS) announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK),...
Innovent Biologics’ Ipilimumab NDA Accepted by CDE with Priority Review for Colon Cancer
China-based Innovent Biologics, Inc. (HKG: 1801) announced that the Center for Drug Evaluation (CDE), National...
Epitopea and Merck Partner to Identify Cryptigen Tumor Antigens
UK-based RNA immunotherapy developer Epitopea announced a licensing and research cooperation agreement with US pharmaceutical...
Hepalink Pharmaceutical’s H1710 Heparanase Inhibitor Approved for Phase I Study
China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) announced that it has received approval...